November 5 to 10, 2018, the first China International Import Expo (CIIE) is set to host in Shanghai. Fosun's 11 portfolio companies and business partners in overseas healthcare sector will attend the expo and showcase Fosun's latest development in the global health industry, exhibiting leading health technology and products including the CAR-T cell therapy treatment, the da Vinci surgical robot systems and other health products and services from Indian generic pharmaceutical maker Gland Pharma, medical laser maker SISRAM MED, homecare ventilation and sleep therapy product maker Breas. Other Fosun healthcare brands, such as British pram maker Silver Cross, French margarine maker St. Hubert, Portugal hospital and medical service provider Luz Saúde, will participate in the exhibition as well.
These companies mainly come from countries and regions such as the U.S., UK, Sweden, India, France and Israel, and cover a wide range of products and services from biopharmaceuticals, medical devices to consumer health, demonstrating Fosun's ability to link global health technology innovations and promote innovation, research and development to help build up a healthy world.
During the CIIE, a global health and technological innovation forum themed "Global Initiative: Building health ecosystem together" will be held by China Pharmaceutical Innovation and Research Development Association, International Health Exchange and Cooperation Center of National Health and Family Planning Commission and Fosun International. As one of the official events at the CIIE, leading figures and experts from the industry will gather at the forum to present the latest trends in global healthcare innovations and discuss ways of cooperation to improve human health.
Innovation is an important means to improve human health. Since its establishment in 1992, Fosun has become an international industrial operation company with its roots in China. Technological innovation has been the driving force behind Fosun's continuous development in the sectors of "Health, Happiness and Wealth."
Health has become a pillar sector in Fosun's customer-to-maker (C2M) ecosystem. The health segment mainly includes Fosun Pharma, Henlius, Fosun Kite, Wanbang Biopharmaceuticals, Yao Pharma, Guilin Pharma, Gland Pharma, Foshan Chancheng Central Hospital, United Family Healthcare, SISRAM MED, Silver Cross, etc.
In recent years, Fosun has been taking technological innovation as its key initiative in the sectors of pharmaceutical manufacturing and R&D, innovative healthcare management service, connecting global health technology resources, and pushing forward the upgrade of China's health industry. In the first half of 2018, RMB 4 billion (USD588 million) was invested into technology initiatives including R&D, venture capital investments, incubation programs, etc.
With its roots in China, Fosun also aims to link health technology innovations worldwide. One initiative is to bring Chinese innovative medicine abroad. The antimalaria medicines, ARTESUN, innovated and produced by Fosun's Guilin Pharma, have saved over 20 million human lives.
As an international company headquartered in Shanghai, Fosun aspires to become a global leader in technology and innovation through adhering to its technological innovation strategy and pushing forward development in health technology, new energy, big data, artificial intelligence, financial technology, etc. It will focus on building up the new technology hub and contribute to the journey of Shanghai becoming the technology and innovation center with global influence.
-------------------------------------------------
Editor's Note:
To apply for becoming a contributor of En-CPhI.cn,
welcome to send your CV and sample works to us,
Email: Julia.Zhang@ubmsinoexpo.com.
(All Rights Reserved)